Pancreatic cancer that has spread and stopped responding to first-line treatment is one of the bleakest diagnoses in oncology. People in that position typically live about six to seven months on chemotherapy. On October 15, the European Medicines Agency's human medicines committee recommended an oral pill that, in a phase 3 trial, roughly doubled that figure.

What the EMA recommended

The committee (CHMP) recommended marketing authorisation in the European Union for Rasonque (daraxonrasib), made by Revolution Medicines, for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment, according to the EMA. The recommendation followed a phased review that let regulators begin assessing data several months before the full application was submitted. The drug had been picked as a high-priority medicine under the EMA's Cancer Medicines Pathfinder project and received orphan designation for pancreatic cancer on April 20, 2026.

The European Commission makes the final decision on authorisation, which normally follows a CHMP opinion. In the United States, the FDA approved daraxonrasib on August 26, 2026, according to OncLive and a published commentary on the trial. The EU opinion therefore arrives seven weeks later.

What the trial found

The evidence comes from RASolute 302, an open-label phase 3 study of 500 patients at 59 sites across North America, Europe and Asia. Patients whose disease had worsened after prior treatment received daraxonrasib or the investigator's choice of chemotherapy.

The EMA's summary reported a median survival of 12.4 months with Rasonque versus 6.7 months with chemotherapy. Results presented at the ASCO meeting in June and published in the New England Journal of Medicine gave 13.2 months versus 6.7, a hazard ratio for death of 0.40, according to the trade journal Targeted Oncology. The two figures use different data cuts, and the EMA's analysis used survival data up to June 15. Either way, the gap is large: the risk of death was reduced by about 60 percent.

Median progression-free survival was 7.2 months versus 3.6, OncLive reported from the CHMP data. In the broader population, the objective response rate was 31.6 percent with daraxonrasib versus 11.2 percent with chemotherapy, according to Cleveland Clinic Journal of Medicine's ASCO coverage.

How it works and what it costs patients

Daraxonrasib is a RAS(ON) inhibitor, designed to block the RAS protein directly. RAS acts as a growth switch inside cells, and mutations in the RAS gene keep it permanently on, driving many cancers. If the Commission authorises the drug, it would be the first broad RAS-targeted treatment available in the EU for metastatic pancreatic cancer, the analysts at Dealroom noted.

The side effects are real but different from chemotherapy's. Rash and stomatitis (mouth sores) were the most common serious events. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of patients on daraxonrasib versus 57.5 percent on chemotherapy, and only 1.2 percent stopped treatment because of side effects, compared with 11.2 percent on chemotherapy, according to trial results reported by Cleveland Clinic Journal of Medicine. Patients also took longer to experience worsening pain (hazard ratio 0.51) and a decline in global quality of life (hazard ratio 0.60).

A separate review in the Journal of Clinical Oncology cautioned that rash, diarrhea and mucositis remained clinically challenging in earlier-phase data, and that it is unclear whether the safety profile will hold in a less selected population.

The caveats worth keeping

The trial was open-label, so patients and doctors knew who was receiving the drug. That matters most for symptom and quality-of-life measures, which are easier to influence than survival. A commentary in the medical literature also argued that the benefit looked so large that doctors and patients lost equipoise early, meaning it became hard to justify randomizing anyone to chemotherapy. That commentary noted the median follow-up was only 8.5 months at the analysis it discussed, so the survival numbers will need to settle as follow-up lengthens.

The patients were also a selected group, those well enough to be enrolled in a global trial after first-line treatment. Real-world patients with worse performance status may do less well. And the study compared the drug with chemotherapy rather than with another targeted approach, because none was available.

None of this cancels the finding. A hazard ratio of 0.40 in this disease is, in the words of one oncologist's review, virtually unprecedented. It means the result is unlikely to be an artifact. But it does explain why regulators are asking for follow-up and why the headline survival numbers differ slightly between sources.

Why this approval is different

Most cancer approvals this month have been incremental. The FDA's decision on Tecentriq for stage III colon cancer, for example, rests on a benefit in preventing relapse, while overall survival has not yet been shown to differ. Daraxonrasib's case is built on survival already measured in a disease where gains have usually been counted in weeks.

The practical questions now move from efficacy to access. The Commission has to authorise it, then national health systems have to decide whether to pay for it and for whom. The next test of the drug's reach is first-line treatment, where a trial called RASolute 303 is examining it, and where the control arm and the question of crossover will matter just as much.

For the patients who are eligible, the date that matters is not the CHMP vote. It is the day a European doctor can write the prescription.

---